Dyne Therapeutics (NASDAQ:DYN) Trading Up 4% – Time to Buy?

Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) traded up 4% during trading on Monday . The company traded as high as $8.24 and last traded at $8.49. 40,225 shares were traded during mid-day trading, a decline of 97% from the average session volume of 1,483,034 shares. The stock had previously closed at $8.17.

Analyst Upgrades and Downgrades

DYN has been the topic of several recent research reports. Chardan Capital reaffirmed a “buy” rating and issued a $50.00 target price on shares of Dyne Therapeutics in a research note on Monday, March 17th. Guggenheim reiterated a “buy” rating on shares of Dyne Therapeutics in a research report on Friday, January 24th. JPMorgan Chase & Co. reduced their price target on Dyne Therapeutics from $18.00 to $17.00 and set a “neutral” rating on the stock in a research report on Friday, March 21st. HC Wainwright reissued a “buy” rating and issued a $46.00 target price on shares of Dyne Therapeutics in a research note on Monday, March 17th. Finally, Scotiabank started coverage on Dyne Therapeutics in a research report on Friday, March 7th. They set a “sector outperform” rating and a $50.00 target price for the company. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, twelve have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, Dyne Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $47.46.

Dyne Therapeutics Stock Up 14.0 %

The company’s fifty day moving average price is $11.14 and its two-hundred day moving average price is $20.31. The company has a market cap of $1.06 billion, a price-to-earnings ratio of -2.62 and a beta of 1.21.

Dyne Therapeutics (NASDAQ:DYN) last announced its earnings results on Tuesday, March 4th. The company reported ($0.88) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.04. On average, equities research analysts predict that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current fiscal year.

Insider Activity at Dyne Therapeutics

In other Dyne Therapeutics news, insider Oxana Beskrovnaya sold 2,598 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total transaction of $36,242.10. Following the transaction, the insider now owns 199,087 shares of the company’s stock, valued at $2,777,263.65. The trade was a 1.29 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last quarter, insiders have sold 6,237 shares of company stock valued at $77,760. 20.77% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. GF Fund Management CO. LTD. acquired a new stake in Dyne Therapeutics during the 4th quarter valued at $50,000. KBC Group NV lifted its holdings in Dyne Therapeutics by 45.3% during the 4th quarter. KBC Group NV now owns 3,135 shares of the company’s stock worth $74,000 after purchasing an additional 978 shares during the last quarter. Summit Investment Advisors Inc. grew its holdings in Dyne Therapeutics by 9.1% in the 4th quarter. Summit Investment Advisors Inc. now owns 8,627 shares of the company’s stock valued at $203,000 after buying an additional 721 shares in the last quarter. Neo Ivy Capital Management acquired a new position in Dyne Therapeutics in the fourth quarter valued at about $205,000. Finally, GAMMA Investing LLC lifted its position in Dyne Therapeutics by 837.5% during the first quarter. GAMMA Investing LLC now owns 2,625 shares of the company’s stock worth $251,000 after purchasing an additional 2,345 shares during the period. 96.68% of the stock is currently owned by institutional investors.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.